The Globe and Mail reports in its Wednesday, Sept. 20, edition that Stifel analyst Justin Keywood has reaffirmed his "buy" recommendation for HLS Therapeutics. The Globe's David Leeder writes that Mr. Keywood slashed his share target back by $2.75 to $12.25. Analysts on average target the shares at $13.63. Mr. Keywood says in a note: "We provide an update on Vascepa Canada Rx data that shows continued progression in prescription count, growing at 91 per cent year-over-year for the month of August. HLS has guided for Vascepa 2023 sales of $18-million to $20-million (22 per cent of total), up 35 per cent year-over-year at the midpoint and expects the drug to generate more than $100-million by 2028. The prescription data trends and a resetting of expectations by HLS' new CEO, highlights still visibility of good growth for several years with above average margins. However, the inflection embedded in 2024 forecasts needs to be reset to what is achievable, barring any new developments. As a result, our target price resets to $12.25 but still showing substantial upside. HLS is trading at nine times/seven times our refined 2023/2024 forecasts, and very reasonable levels for the growth and margin profile ahead."